Suppr超能文献

益生菌或合生菌在危重症患者中的疗效:系统评价和荟萃分析。

Efficacy of probiotics or synbiotics in critically ill patients: A systematic review and meta-analysis.

机构信息

Burn Department, Ningbo No. 2 Hospital, Ningbo, Zhejiang Province, China.

Burn Department, Ningbo No. 2 Hospital, Ningbo, Zhejiang Province, China.

出版信息

Clin Nutr ESPEN. 2024 Feb;59:48-62. doi: 10.1016/j.clnesp.2023.11.003. Epub 2023 Nov 8.

Abstract

BACKGROUND

This latest systematic review and meta-analysis aim to examine the effects of probiotic and synbiotic supplementation in critically ill patients.

METHODS

Relevant articles were retrieved from PubMed, Embase, the Cochrane Database, and the Web of Science. The primary output measure was the incident of ventilator-associated pneumonia, and the secondary outputs were diarrhea, Clostridium diffusion infection (CDI), incident of sepsis, incident of hospital acquired pneumonia, duration of mechanical exploitation, ICU mortality rate, length of ICU stay, in hospital mortality, and length of hospital stay. Data were pooled and expressed as Relative Risk(RR) and Standardized Mean Difference (SMD) with a 95 % confidence interval (CI).

RESULTS

33 studies were included in this systematic review and meta-analysis, with 4065 patients who received probiotics or synbiotics (treatment group) and 3821 patients who received standard care or placebo (control group). The pooled data from all included studies demonstrated that the treatment group has significantly reduced incidence of ventilation-associated pneumonia (VAP) (RR = 0.80; 95 % CI: 0.67-0.96; p = 0.021, I = 52.5 %) and sepsis (RR = 0.97; 95 % CI: 0.66-1.42; p = 0.032, I = 54.4 %), As well as significantly increased duration of mechanical exploitation (SMD = -0.47; 95 % CI: -0.74-0.20, p = 0.012, I = 63.4 %), ICU mobility (RR = 0.95; 95 % CI: 0.71-1.27; p = 0.004, I = 62.8 %), length of ICU stay (SMD = -0.29; 95 % CI: -0.58-0.01; p = 0.000, I = 82.3 %) and length of hospital stay (SMD = -0.33; 95 % CI: -0.57-0.08, p = 0.000, I = 74.2 %) than the control group. There were no significant differences in diarrhea, CDI, incidence of hospital acquired pneumonia, and in hospital mortality between the two groups.

CONCLUSION

Our meta-analysis showed that probiotic and synbiotic supplements are beneficial for critically ill patients as they significantly reduce the incidence of ventilator associated pneumonia and sepsis, as well as the duration of mechanical exploitation, length of hospital stay, length of ICU stay, and ICU mortality. However, this intervention has minimal impact on diarrhea, CDI, incidence of hospital acquired pneumonia, and in hospital mortality in critically ill patients.

摘要

背景

本最新的系统评价和荟萃分析旨在研究益生菌和合生菌补充剂对危重症患者的影响。

方法

从 PubMed、Embase、Cochrane 数据库和 Web of Science 检索相关文章。主要输出指标为呼吸机相关性肺炎的发生率,次要输出指标为腹泻、艰难梭菌扩散感染(CDI)、脓毒症发生率、医院获得性肺炎发生率、机械通气时间、重症监护病房死亡率、重症监护病房住院时间、院内死亡率和住院时间。数据进行合并并表示为相对风险(RR)和标准化均数差(SMD),置信区间(CI)为 95%。

结果

本系统评价和荟萃分析共纳入 33 项研究,共纳入 4065 例接受益生菌或合生菌(治疗组)和 3821 例接受标准治疗或安慰剂(对照组)的患者。所有纳入研究的汇总数据表明,治疗组呼吸机相关性肺炎(VAP)的发生率显著降低(RR=0.80;95%CI:0.67-0.96;p=0.021,I²=52.5%)和脓毒症(RR=0.97;95%CI:0.66-1.42;p=0.032,I²=54.4%),同时机械通气时间(SMD=-0.47;95%CI:-0.74-0.20,p=0.012,I²=63.4%)、重症监护病房周转率(RR=0.95;95%CI:0.71-1.27;p=0.004,I²=62.8%)、重症监护病房住院时间(SMD=-0.29;95%CI:-0.58-0.01;p=0.000,I²=82.3%)和住院时间(SMD=-0.33;95%CI:-0.57-0.08,p=0.000,I²=74.2%)均显著延长。两组之间腹泻、CDI、医院获得性肺炎和院内死亡率无显著差异。

结论

我们的荟萃分析表明,益生菌和合生菌补充剂对危重症患者有益,因为它们可显著降低呼吸机相关性肺炎和脓毒症的发生率,以及机械通气时间、住院时间、重症监护病房住院时间和重症监护病房死亡率。然而,这种干预对危重症患者的腹泻、CDI、医院获得性肺炎和院内死亡率影响较小。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验